MARKET

MACK

MACK

Merrimack Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.580
+0.178
+5.23%
After Hours: 3.580 0 0.00% 16:00 01/24 EST
OPEN
3.410
PREV CLOSE
3.402
HIGH
3.600
LOW
3.380
VOLUME
38.61K
TURNOVER
--
52 WEEK HIGH
5.51
52 WEEK LOW
3.050
MARKET CAP
47.84M
P/E (TTM)
-1.4316
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of MACK and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 2 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

MACK News

  • The Daily Biotech Pulse: Osmotica Soars On Insider Buys, Ultragenyx's Partnered Rare Disease Drug Moves Into Clinics
  • Benzinga.01/16 12:22
  • Hedge Funds Are Selling Merrimack Pharmaceuticals Inc (MACK)
  • Insider Monkey.12/23/2019 00:44
  • The Daily Biotech Pulse: Axovant Surges On Gene Therapy Study Results, FDA Approves Merck's Ebola Vaccine, Abeona Announces Offering
  • Benzinga.12/20/2019 13:12
  • Merrimack Pharmaceuticals declares $0.50 dividend
  • seekingalpha.12/03/2019 18:49

More

Industry

Biotechnology & Medical Research
-2.64%
Pharmaceuticals & Medical Research
-2.00%

Hot Stocks

Name
Price
%Change

About MACK

Merrimack Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in designing novel treatments for cancer by targeting biomarker-defined cancers. Its clinical programs include MM-121 (seribantumab), MM-141 (istiratumab) and MM-310. MM-121 is a fully human monoclonal antibody that binds to the ErbB3 (HER3) receptor and targets heregulin positive cancers. MM-141 is a fully human tetravalent bispecific antibody designed to block tumor survival signals by targeting receptor complexes containing the insulin-like growth factor 1, or IGF-1, receptor and ErbB3 (HER3) cell surface receptor. MM-310 is an antibody-directed nanotherapeutic that targets the ephrin receptor A2, or EphA2, receptor and contains a novel prodrug of the highly potent chemotherapy docetaxel. The Company’s preclinical programs include MM-161, ATRi, BCL2/BCLxl, TRAIL, Immuno-oncology and STIMULI.
More

Webull offers Merrimack Pharmaceuticals Inc (MACK) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.